Bayer Aktiengesellschaft’s Pharmaceuticals Division showcased robust momentum at the 44th Annual J.P. Morgan Healthcare Conference. Head of the division Stefan Oelrich highlighted 2025 as a landmark year, with five pivotal worldwide approvals validating Bayer’s strategic execution. He noted near-term top-line growth drivers in oncology, cardiology and women’s health, and emphasized organizational efficiencies achieved through delayering and cost reductions. Investors were particularly encouraged by a diversified modality-rich pipeline, with new assets progressing rapidly through clinical stages and Fast Track Designations secured in key markets.

Bayer has set clear financial objectives for its Pharmaceuticals Division: a return to mid-single-digit percentage growth by no later than 2027 and an operating margin of approximately 30% by 2030. These targets are underpinned by commercial expansion of recently launched products, regulatory filings underway in the EU, U.S. and China, and portfolio rationalization efforts. Management reaffirmed commitment to capital discipline, forecasting R&D investment levels to remain below 20% of division sales, while channeling funds toward high-value programs and profitable geographies.

Bayer’s cardiovascular portfolio achieved significant milestones in 2025. Phase III OCEANIC-STROKE data for asundexian, an oral Factor XIa inhibitor for secondary stroke prevention, met primary safety and efficacy endpoints, positioning it for blockbuster potential under Fast Track status with the U.S. FDA. Kerendia® (finerenone) gained FDA and Japanese MHLW approval for heart failure patients with left ventricular ejection fraction ≥40%, extending its chronic kidney disease indication in type 2 diabetes. Late-breaking Phase III FINE-ONE results also supported Kerendia’s expanded use. Additional pipeline assets—AB-1002 gene therapy for congestive heart failure and BAY-3018250 antibody for targeted thrombolysis—entered mid-stage trials, reflecting Bayer’s ambition to lead in cardiovascular-renal metabolic conditions.

Bayer’s oncology franchise continues to be a growth engine. Nubeqa® (darolutamide) has treated over 200,000 patients worldwide across three prostate cancer indications, with global sales trending upward and a third approval in China expected in 2026. Hyrnuo® (sevabertinib) received accelerated FDA approval for HER2-mutant non-small cell lung cancer after Breakthrough Therapy designations in the U.S. and China based on SOHO-01 study results. Radium-223 dichloride (Xofigo®) combination data from the EORTC PEACE III trial met its primary endpoint, reinforcing Bayer’s leadership in targeted radionuclide therapy for metastatic prostate cancer. The oncology pipeline further includes KRAS-targeted agents, next-generation alpha therapies and PRMT5 inhibitors, ensuring a steady cadence of clinical milestones through 2028.